Prognostiska faktorer kan delas in i<\/p>\n
Prognostiska faktorer kan anv\u00e4ndas b\u00e5de hos patienter med lokal sjukdom (prediktiv risk f\u00f6r recidiv) och hos patienter med avancerad sjukdom (ger en uppskattning av median\u00f6verlevnaden). Generellt rekommenderas att TNM och histopatologiska faktorer anv\u00e4nds f\u00f6r lokal sjukdom och den kliniska prognosmodell som IMDC tagit fram f\u00f6r patienter med spridd sjukdom.<\/p>\n<\/div>\n<\/section>\n<\/div>
TNM-klassificeringen anv\u00e4nds h\u00e4r (Se avsnittet om anatomisk stadieindelning av njurcancer<\/a>)<\/a>. Generellt g\u00e4ller att ju h\u00f6gre stadium, desto s\u00e4mre prognos.<\/span><\/p>\n<\/div>Histopatologiska prognostiska faktorer<\/h4><\/div>Se avsnittet om historisk klassificering av RCC<\/a><\/p>\nDetta inkluderar f\u00f6ljande parametrar:<\/p>\n\nSubtyp av RCC<\/li>\nWHO:s och Fuhrmans graderingssystem<\/li>\nK\u00e4rlinvasion<\/li>\nTum\u00f6rnekros<\/li>\nF\u00f6rekomst av sarkomatoid\/rabdoid dedifferentiering<\/li>\n<\/ul>\n<\/div>Kliniska prognostiska faktorer<\/h4><\/div>\nFunktionsstatus<\/a><\/li>\nSymtom p\u00e5 cancer<\/li>\nAnemi<\/li>\nNeutrofil-\/lymfocytkvot<\/li>\nCRP<\/li>\n<\/ul>\nPrognostiska modeller som inneh\u00e5ller flera kliniska faktorer, t.ex. IMDC<\/a>,<\/a> anv\u00e4nds f\u00f6r att stratifiera patienter med spridd njurcancer.<\/p>\n<\/div>Molekyl\u00e4ra\/genomiska faktorer<\/h4><\/div>Samband har p\u00e5visats mellan flera mutationer, bland annat PBRM1, SETD2 och BAP1, och risk f\u00f6r recidiv eller s\u00e4mre \u00f6verlevnad. Detta anv\u00e4nds dock inte rutinm\u00e4ssigt i den kliniska v\u00e5rden.<\/p>\n<\/div><\/div><\/div><\/div><\/div>Referenser<\/h4><\/div>\nPrognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/em><\/li>\nEAU guidelines on renal cell carcinoma:<\/em><\/li>\nB. Ljungberg (Chair), L. Albiges, K. Bensalah, A. Bex (Vice-chair), R.H. Giles (Patient Advocate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi, A.S. Merseburger, T. Powles,M. Staehler, A. Volpe Guidelines Associates: S. Dabestani, S. Fern\u00e1ndez-Pello Montes, F. Hofmann, R. Tahbaz<\/em><\/li>\nRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020<\/em><\/li>\nB. Escudier1, C. Porta2, M. Schmidinger3, N. Rioux-Leclercq4, A. Bex5, V. Khoo6,7, V. Gruenvald8 & A. Horwich9 on behalf of the ESMO Guidelines Committee*<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div>Testa dina kunskaper<\/h4><\/div><\/div><\/div><\/div><\/div>Prognostiska faktorer kan delas in i<\/h5><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Anatomiska, histopatologiska, kliniska<\/label><\/div>Histopatologiska, anatomiska, molekyl\u00e4ra\/genomiska<\/label><\/div>Anatomiska, histopatologiska, kliniska, molekyl\u00e4ra\/genomiska<\/label><\/div><\/fieldset><\/div>(Anv\u00e4ndning av quizen \u00e4r helt anonym!)<\/small><\/p>\n<\/div><\/div><\/div><\/i><\/div>\n<\/div>Det \u00e4r r\u00e4tt!<\/p>\n<\/div><\/i><\/div><\/p>\n<\/div>Det \u00e4r fel!<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/form><\/div>Forts\u00e4tt till n\u00e4sta avsnitt: 3.1 Behandlingsalgoritm<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/span>Utforska den h\u00e4r kapitelmenyn<\/p><\/h5><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div>2.1 Symtom p\u00e5 njurcancer<\/span><\/i><\/a><\/div>2.2 Utredning av misst\u00e4nkt njurcancer<\/span><\/i><\/a><\/div>2.3 Multidisciplin\u00e4r konferens (MDK)<\/span><\/i><\/a><\/div>2.4 Verktyg f\u00f6r prognostisk stratifiering av patienter med mRCC<\/span><\/i><\/a><\/div>2.5 Prognostiska faktorer<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7490,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":9,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":11170,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions\/11170"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7490"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Se avsnittet om historisk klassificering av RCC<\/a><\/p>\nDetta inkluderar f\u00f6ljande parametrar:<\/p>\n\nSubtyp av RCC<\/li>\nWHO:s och Fuhrmans graderingssystem<\/li>\nK\u00e4rlinvasion<\/li>\nTum\u00f6rnekros<\/li>\nF\u00f6rekomst av sarkomatoid\/rabdoid dedifferentiering<\/li>\n<\/ul>\n<\/div>Kliniska prognostiska faktorer<\/h4><\/div>\nFunktionsstatus<\/a><\/li>\nSymtom p\u00e5 cancer<\/li>\nAnemi<\/li>\nNeutrofil-\/lymfocytkvot<\/li>\nCRP<\/li>\n<\/ul>\nPrognostiska modeller som inneh\u00e5ller flera kliniska faktorer, t.ex. IMDC<\/a>,<\/a> anv\u00e4nds f\u00f6r att stratifiera patienter med spridd njurcancer.<\/p>\n<\/div>Molekyl\u00e4ra\/genomiska faktorer<\/h4><\/div>Samband har p\u00e5visats mellan flera mutationer, bland annat PBRM1, SETD2 och BAP1, och risk f\u00f6r recidiv eller s\u00e4mre \u00f6verlevnad. Detta anv\u00e4nds dock inte rutinm\u00e4ssigt i den kliniska v\u00e5rden.<\/p>\n<\/div><\/div><\/div><\/div><\/div>Referenser<\/h4><\/div>\nPrognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/em><\/li>\nEAU guidelines on renal cell carcinoma:<\/em><\/li>\nB. Ljungberg (Chair), L. Albiges, K. Bensalah, A. Bex (Vice-chair), R.H. Giles (Patient Advocate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi, A.S. Merseburger, T. Powles,M. Staehler, A. Volpe Guidelines Associates: S. Dabestani, S. Fern\u00e1ndez-Pello Montes, F. Hofmann, R. Tahbaz<\/em><\/li>\nRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020<\/em><\/li>\nB. Escudier1, C. Porta2, M. Schmidinger3, N. Rioux-Leclercq4, A. Bex5, V. Khoo6,7, V. Gruenvald8 & A. Horwich9 on behalf of the ESMO Guidelines Committee*<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div>Testa dina kunskaper<\/h4><\/div><\/div><\/div><\/div><\/div>Prognostiska faktorer kan delas in i<\/h5><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Anatomiska, histopatologiska, kliniska<\/label><\/div>Histopatologiska, anatomiska, molekyl\u00e4ra\/genomiska<\/label><\/div>Anatomiska, histopatologiska, kliniska, molekyl\u00e4ra\/genomiska<\/label><\/div><\/fieldset><\/div>(Anv\u00e4ndning av quizen \u00e4r helt anonym!)<\/small><\/p>\n<\/div><\/div><\/div><\/i><\/div>\n<\/div>Det \u00e4r r\u00e4tt!<\/p>\n<\/div><\/i><\/div><\/p>\n<\/div>Det \u00e4r fel!<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/form><\/div>Forts\u00e4tt till n\u00e4sta avsnitt: 3.1 Behandlingsalgoritm<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/span>Utforska den h\u00e4r kapitelmenyn<\/p><\/h5><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div>2.1 Symtom p\u00e5 njurcancer<\/span><\/i><\/a><\/div>2.2 Utredning av misst\u00e4nkt njurcancer<\/span><\/i><\/a><\/div>2.3 Multidisciplin\u00e4r konferens (MDK)<\/span><\/i><\/a><\/div>2.4 Verktyg f\u00f6r prognostisk stratifiering av patienter med mRCC<\/span><\/i><\/a><\/div>2.5 Prognostiska faktorer<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7490,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":9,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":11170,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions\/11170"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7490"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Detta inkluderar f\u00f6ljande parametrar:<\/p>\n
Prognostiska modeller som inneh\u00e5ller flera kliniska faktorer, t.ex. IMDC<\/a>,<\/a> anv\u00e4nds f\u00f6r att stratifiera patienter med spridd njurcancer.<\/p>\n<\/div>Molekyl\u00e4ra\/genomiska faktorer<\/h4><\/div>Samband har p\u00e5visats mellan flera mutationer, bland annat PBRM1, SETD2 och BAP1, och risk f\u00f6r recidiv eller s\u00e4mre \u00f6verlevnad. Detta anv\u00e4nds dock inte rutinm\u00e4ssigt i den kliniska v\u00e5rden.<\/p>\n<\/div><\/div><\/div><\/div><\/div>Referenser<\/h4><\/div>\nPrognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/em><\/li>\nEAU guidelines on renal cell carcinoma:<\/em><\/li>\nB. Ljungberg (Chair), L. Albiges, K. Bensalah, A. Bex (Vice-chair), R.H. Giles (Patient Advocate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi, A.S. Merseburger, T. Powles,M. Staehler, A. Volpe Guidelines Associates: S. Dabestani, S. Fern\u00e1ndez-Pello Montes, F. Hofmann, R. Tahbaz<\/em><\/li>\nRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020<\/em><\/li>\nB. Escudier1, C. Porta2, M. Schmidinger3, N. Rioux-Leclercq4, A. Bex5, V. Khoo6,7, V. Gruenvald8 & A. Horwich9 on behalf of the ESMO Guidelines Committee*<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div>Testa dina kunskaper<\/h4><\/div><\/div><\/div><\/div><\/div>Prognostiska faktorer kan delas in i<\/h5><\/div><\/div><\/div><\/div><\/div><\/div><\/div>Anatomiska, histopatologiska, kliniska<\/label><\/div>Histopatologiska, anatomiska, molekyl\u00e4ra\/genomiska<\/label><\/div>Anatomiska, histopatologiska, kliniska, molekyl\u00e4ra\/genomiska<\/label><\/div><\/fieldset><\/div>(Anv\u00e4ndning av quizen \u00e4r helt anonym!)<\/small><\/p>\n<\/div><\/div><\/div><\/i><\/div>\n<\/div>Det \u00e4r r\u00e4tt!<\/p>\n<\/div><\/i><\/div><\/p>\n<\/div>Det \u00e4r fel!<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/form><\/div>Forts\u00e4tt till n\u00e4sta avsnitt: 3.1 Behandlingsalgoritm<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/span>Utforska den h\u00e4r kapitelmenyn<\/p><\/h5><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div>2.1 Symtom p\u00e5 njurcancer<\/span><\/i><\/a><\/div>2.2 Utredning av misst\u00e4nkt njurcancer<\/span><\/i><\/a><\/div>2.3 Multidisciplin\u00e4r konferens (MDK)<\/span><\/i><\/a><\/div>2.4 Verktyg f\u00f6r prognostisk stratifiering av patienter med mRCC<\/span><\/i><\/a><\/div>2.5 Prognostiska faktorer<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7490,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":9,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":11170,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions\/11170"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7490"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Samband har p\u00e5visats mellan flera mutationer, bland annat PBRM1, SETD2 och BAP1, och risk f\u00f6r recidiv eller s\u00e4mre \u00f6verlevnad. Detta anv\u00e4nds dock inte rutinm\u00e4ssigt i den kliniska v\u00e5rden.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
(Anv\u00e4ndning av quizen \u00e4r helt anonym!)<\/small><\/p>\n<\/div><\/div><\/div><\/i><\/div>\n<\/div>Det \u00e4r r\u00e4tt!<\/p>\n<\/div><\/i><\/div><\/p>\n<\/div>Det \u00e4r fel!<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/form><\/div>Forts\u00e4tt till n\u00e4sta avsnitt: 3.1 Behandlingsalgoritm<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/span>Utforska den h\u00e4r kapitelmenyn<\/p><\/h5><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div>2.1 Symtom p\u00e5 njurcancer<\/span><\/i><\/a><\/div>2.2 Utredning av misst\u00e4nkt njurcancer<\/span><\/i><\/a><\/div>2.3 Multidisciplin\u00e4r konferens (MDK)<\/span><\/i><\/a><\/div>2.4 Verktyg f\u00f6r prognostisk stratifiering av patienter med mRCC<\/span><\/i><\/a><\/div>2.5 Prognostiska faktorer<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7490,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":9,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":11170,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions\/11170"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7490"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Det \u00e4r r\u00e4tt!<\/p>\n<\/div>
Det \u00e4r fel!<\/p>\n<\/div>\n<\/div><\/div>
Utforska den h\u00e4r kapitelmenyn<\/p><\/h5><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div>2.1 Symtom p\u00e5 njurcancer<\/span><\/i><\/a><\/div>2.2 Utredning av misst\u00e4nkt njurcancer<\/span><\/i><\/a><\/div>2.3 Multidisciplin\u00e4r konferens (MDK)<\/span><\/i><\/a><\/div>2.4 Verktyg f\u00f6r prognostisk stratifiering av patienter med mRCC<\/span><\/i><\/a><\/div>2.5 Prognostiska faktorer<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7490,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7510","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/comments?post=7510"}],"version-history":[{"count":9,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions"}],"predecessor-version":[{"id":11170,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7510\/revisions\/11170"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/pages\/7490"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/sv\/wp-json\/wp\/v2\/media?parent=7510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}